Pharma-Bio Serv Announces Results for the Quarter Ended January 31, 2025
Pharma-Bio Serv (OTCQB:PBSV), a compliance and consulting firm serving pharmaceutical and related industries, reported financial results for Q1 2025. The company achieved revenues of $2.5 million for the quarter ended January 31, 2025, marking a $0.1 million increase compared to the same period last year.
The company reached near breakeven net income, showing significant improvement with a $0.3 million earnings increase year-over-year. The company currently has ongoing projects across Europe, Asia, and Latin America, positioning itself for continued market expansion.
Pharma-Bio Serv (OTCQB:PBSV), una società di consulenza e conformità che serve le industrie farmaceutiche e correlate, ha riportato i risultati finanziari per il primo trimestre del 2025. L'azienda ha registrato entrate di 2,5 milioni di dollari per il trimestre conclusosi il 31 gennaio 2025, segnando un aumento di 0,1 milioni di dollari rispetto allo stesso periodo dell'anno scorso.
L'azienda ha raggiunto quasi un reddito netto in pareggio, mostrando un miglioramento significativo con un aumento degli utili di 0,3 milioni di dollari rispetto all'anno precedente. Attualmente, l'azienda ha progetti in corso in Europa, Asia e America Latina, posizionandosi per una continua espansione del mercato.
Pharma-Bio Serv (OTCQB:PBSV), una firma de cumplimiento y consultoría que sirve a las industrias farmacéuticas y relacionadas, reportó resultados financieros para el primer trimestre de 2025. La compañía logró ingresos de 2.5 millones de dólares para el trimestre que finalizó el 31 de enero de 2025, marcando un aumento de 0.1 millones de dólares en comparación con el mismo período del año pasado.
La compañía alcanzó un ingreso neto casi equilibrado, mostrando una mejora significativa con un aumento de ganancias de 0.3 millones de dólares año tras año. Actualmente, la empresa tiene proyectos en curso en Europa, Asia y América Latina, posicionándose para una continua expansión del mercado.
Pharma-Bio Serv (OTCQB:PBSV), 제약 및 관련 산업을 위한 준수 및 컨설팅 회사가 2025년 1분기 재무 결과를 발표했습니다. 이 회사는 2025년 1월 31일로 끝나는 분기에 250만 달러의 수익을 기록했으며, 이는 지난해 같은 기간에 비해 10만 달러 증가한 수치입니다.
회사는 손익 분기점에 가까운 순이익을 달성했으며, 전년 대비 30만 달러의 수익 증가를 보여주는 상당한 개선을 보였습니다. 현재 이 회사는 유럽, 아시아 및 라틴 아메리카에서 진행 중인 프로젝트를 보유하고 있으며, 지속적인 시장 확장을 위해 포지셔닝하고 있습니다.
Pharma-Bio Serv (OTCQB:PBSV), une société de conformité et de conseil servant les industries pharmaceutiques et connexes, a annoncé ses résultats financiers pour le premier trimestre 2025. L'entreprise a réalisé des revenus de 2,5 millions de dollars pour le trimestre se terminant le 31 janvier 2025, marquant une augmentation de 0,1 million de dollars par rapport à la même période l'année dernière.
L'entreprise a atteint un revenu net presque équilibré, montrant une amélioration significative avec une augmentation des bénéfices de 0,3 million de dollars d'une année sur l'autre. Actuellement, l'entreprise a des projets en cours en Europe, en Asie et en Amérique latine, se positionnant pour une expansion continue sur le marché.
Pharma-Bio Serv (OTCQB:PBSV), ein Compliance- und Beratungsunternehmen, das die pharmazeutische Industrie und verwandte Bereiche bedient, hat die finanziellen Ergebnisse für das erste Quartal 2025 veröffentlicht. Das Unternehmen erzielte Einnahmen von 2,5 Millionen Dollar für das am 31. Januar 2025 endende Quartal, was einem Anstieg von 0,1 Millionen Dollar im Vergleich zum gleichen Zeitraum des Vorjahres entspricht.
Das Unternehmen erreichte nahezu ein ausgeglichenes Nettoeinkommen und zeigte eine signifikante Verbesserung mit einem Gewinnanstieg von 0,3 Millionen Dollar im Jahresvergleich. Das Unternehmen hat derzeit laufende Projekte in Europa, Asien und Lateinamerika und positioniert sich für eine fortgesetzte Marktexpansion.
- Revenue increased by $0.1 million to $2.5 million year-over-year
- Earnings improved by $0.3 million, reaching near breakeven
- Geographic expansion with active projects in Europe, Asia, and Latin America
- Company still not profitable despite improvement, operating at breakeven
DORADO, PUERTO RICO / ACCESS Newswire / March 17, 2025 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced that revenues for the quarter ended January 31, 2025 were approximately
"As reflected in this quarter's results, we began experiencing net revenue growth in the markets we serve. With projects underway in Europe, Asia, and Latin America, we are poised for continued expansion as we drive growth by anticipating client needs and delivering unmatched solutions," stated Mr. Sanchez, Chief Executive Officer of the Company.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv services the Puerto Rico, United States, Europe and Latin America markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2024, and in its other filings with the Securities and Exchange Commission, which filings are available at www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787 278 2709
SOURCE: Pharma-Bio Serv Inc.
View the original press release on ACCESS Newswire
FAQ
What was Pharma-Bio Serv's (PBSV) revenue for Q1 2025?
How much did Pharma-Bio Serv's (PBSV) earnings improve in Q1 2025?
Which geographical markets does Pharma-Bio Serv (PBSV) currently operate in?
What was the year-over-year revenue growth for Pharma-Bio Serv (PBSV) in Q1 2025?
